nach oben

10.06.2024 | Original Article

Risk Prediction Model for Surgical Complications and Predictors of Delay/Omission of Adjuvant Chemotherapy Post Primary Cytoreduction in Epithelial Ovarian Cancer

verfasst von: Alka Dahiya, Rachel George, Anitha Thomas, Vinotha Thomas, Ajit Sebastian, Abraham Peedicayil

Erschienen in: Indian Journal of Surgery

Einloggen, um Zugang zu erhalten

Abstract

A risk prediction model for surgical complications post-primary cytoreduction in epithelial ovarian cancer was developed along with determination of factors causing delay/omission of adjuvant chemotherapy. An ambi-directional cohort study was done, including stage II–IV epithelial ovarian, fallopian tube, and primary peritoneal carcinoma patients who underwent primary cytoreduction between January 01, 2016, and December 31, 2020. Clavien-Dindo classification was used to grade surgical complications. Adjuvant treatment was considered delayed if initiated >28 days of surgery. Modified Poisson regression method was used to estimate risk ratios (RR). Of 164 patients, 48 (29.2%) had grade III–V complications. Performance status of ECOG 2 (RR 3.27), surgical duration ≥ 4 h (RR 3.01), diaphragm stripping/resection (RR 2.05), and large bowel resection (RR 2.46) were independent risk factors. For an optimal score cutoff of ≥ 2.8, the discrimination between patients with and without complications was 80.0% (area under curve 0.80, p = 0.001). A risk model built using this score predicted major complications in 65% of cases. The median time to start adjuvant chemotherapy was 28 (10–77) days. Sixty-three (38.4%) patients had a delay, and 18 (10.9%) did not receive adjuvant treatment. Extended hospital stay (RR 1.08) and grade III–IV complications (RR 1.83) delayed chemotherapy, while low albumin (RR 2.15), postoperative ascites (RR 3.67), surgical site infections (RR 2.93), and poor social support (RR 2.70) resulted in omission. Performance status of ECOG 2 and prolonged surgery with diaphragmatic/large bowel resection predict major postoperative complications. Low albumin, grade III/IV complications, and extended hospital stay along with poor social support cause omission/delay in initiation of adjuvant chemotherapy.

Nur mit Berechtigung zugänglich

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H (2019) Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health 11:287–299. https://doi.org/10.2147/IJWH.S197604CrossRefPubMedPubMedCentral

Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 69(4):280–304. https://doi.org/10.3322/caac.21559CrossRefPubMed

Ledermann JA, Raja FA, Fotopoulou C, et al (2013) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6):vi24–32. Available at: http://www.ncbi.nlm.nih.gov/pubmed/24078660

Benedetti Panici P, Di Donato V, Fischetti M, Casorelli A, Perniola G, Musella A et al (2015) Predictors of post-operative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery. Gynecol Oncol. 137(3):406–11. https://doi.org/10.1016/j.ygyno.2015.03.043CrossRefPubMed

Gerestein CG, Damhuis RA, Burger CW, Kooi GS (2009) Post-operative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: asystematic review. Gynecol Oncol 114(3):523–7. https://doi.org/10.1016/j.ygyno.2009.03.011CrossRefPubMed

Gao B, Lindemann K, Anderson L, Fereday S, Hung J, Alsop K et al (2016) Australian Ovarian Cancer Study Group, Harnett PR, Bowtell DD, DeFazio A Serous ovarian and primary peritoneal cancers: a comparative analysis of clinicopathological features, molecular subtypes and treatment outcome. Gynecol Oncol 142(3):458–64. https://doi.org/10.1016/j.ygyno.2016.06.023CrossRefPubMed

Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V et al (2020) Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 30(11):1657–1664. https://doi.org/10.1136/ijgc-2020-001640CrossRefPubMed

Wright JD, Herzog TJ, Neugut AI, Burke WM, Lu YS, Lewin SN et al (2012) Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer. Obstet Gynecol 120(4):871–81. https://doi.org/10.1097/AOG.0b013e31826981deCrossRefPubMed

Alexander M et al (2017) Timely initiation of chemotherapy: a systematic literature review of six priority cancers - results and recommendations for clinical practice. Intern Med J 47:16–34. https://doi.org/10.1111/imj.13190CrossRefPubMed

10.

Lydiksen L, Jensen-Fangel S, Blaakaer J (2014) Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer? Gynecol Oncol 133(3):454–459. https://doi.org/10.1016/j.ygyno.2014.04.004CrossRefPubMed

11.

Liu XD, Liu Y, Gong TT, Guo JY, Wang YN, Wang L, Wu QJ, Jiao YS (2018) Prognostic influence of the time interval between surgery and chemotherapy in epithelial ovarian cancer. J Cancer 9(22):4172–4178. https://doi.org/10.7150/jca.27409CrossRefPubMedPubMedCentral

12.

Seagle BL, Butler SK, Strohl AE, Nieves-Neira W, Shahabi S (2017) Chemotherapy delay after primary debulking surgery for ovarian cancer. Gynecol Oncol 144(2):260–265. https://doi.org/10.1016/j.ygyno.2016.11.022CrossRefPubMed

13.

Timmermans M, van der Aa MA, Lalisang RI, Witteveen PO, Van de Vijver KK, Kruitwagen RF et al (2018) Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer. Gynecol Oncol 150(3):446–450. https://doi.org/10.1016/j.ygyno.2018.07.004CrossRefPubMed

14.

Aletti GD, Long HJ, Podratz KC, Cliby WA (2007) Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer? Gynecol Oncol 104:212–6. https://doi.org/10.1016/j.ygyno.2006.07.045CrossRefPubMed

15.

Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet AG, Vergote I (2013) The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study. Gynecol Oncol 131(1):15–20. https://doi.org/10.1016/j.ygyno.2013.07.086CrossRefPubMed

16.

Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213. https://doi.org/10.1097/01.sla.0000133083.54934.aeCrossRefPubMedPubMedCentral

17.

Ananthan VA (2021) Modified Kuppuswamy scale for socioeconomic status of the Indian family- update based on new CPI (IW) series from September 2020. J Family Med Prim Care 10(5):2048–2049. https://doi.org/10.4103/jfmpc.jfmpc_2242_20CrossRefPubMedPubMedCentral

18.

Nishikimi K, Tate S, Kato K, Matsuoka A, Shozu M (2020) Well-trained gynecologic oncologists can perform bowel resection and upper abdominal surgery safely. J Gynecol Oncol 31(1):e3. https://doi.org/10.3802/jgo.2020.31.e3

19.

Earle CC, Schrag D, Neville BA, Yabroff KR, Topor M, Fahey A et al (2006) Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 98(3):172–80. https://doi.org/10.1093/jnci/djj019CrossRefPubMed

20.

Rottmann M, Burges A, Mahner S et al (2017) Cancer of the ovary, fallopian tube, and peritoneum: a population-based comparison of the prognostic factors and outcomes. J Cancer Res Clin Oncol 143(9):1833–1844. https://doi.org/10.1007/s00432-017-2422-6CrossRefPubMed

21.

McGuire WP et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334(1):1–6. https://doi.org/10.1056/NEJM199601043340101CrossRefPubMed

22.

Pignata S, C Cecere S, Du Bois A, Harter P, Heitz F (2017) Treatment of recurrent ovarian cancer. Ann Oncol 28(suppl_8):viii51–viii56. https://doi.org/10.1093/annonc/mdx441

23.

Gerestein CG, Nieuwenhuyzen-de Boer GM, Eijkemans MJ, Kooi GS, Burger CW (2010) Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer 46(1):102–9. https://doi.org/10.1016/j.ejca.2009.10.017CrossRefPubMed

24.

Obermair A, Hagenauer S, Tamandl D, Clayton RD, Nicklin JL, Perrin LC et al (2001) Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol 83:115–120. https://doi.org/10.1006/gyno.2001.6353CrossRefPubMed

25.

Ataseven B, du Bois A, Reinthaller A et al (2015) Preoperative serum albumin is associated with post- operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery. Gynecol Oncol 138(3):560–565. https://doi.org/10.1016/j.ygyno.2015.07.005CrossRefPubMed

26.

Llueca A, Serra A, Maiocchi K, Delgado K, Jativa R, Gomez L et al (2019) Predictive model for major complications after extensive abdominal surgery in primary advanced ovarian cancer. Int J Womens Health 7(11):161–167. https://doi.org/10.2147/IJWH.S190493CrossRef

27.

Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J et al (2010) The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol 119:38–42. https://doi.org/10.1016/j.ygyno.2010.05.031CrossRefPubMed

28.

Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ (2005) Participants in the VA National Surgical Quality Improvement Program. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg 242(3):326–41. https://doi.org/10.1097/01.sla.0000179621.33268.83

29.

Wright JD, Herzog TJ, Siddiq Z, Arend R, Neugut AI, Burke WM et al (2012) Failure to rescue as a source of variation in hospital mortality for ovarian cancer. J Clin Oncol 30(32):3976–82. https://doi.org/10.1200/JCO.2012.43.2906CrossRefPubMed

30.

Wright J, Doan T, McBride R, Jacobson J, Hershman D (2008) Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer 98(7):1197–203. https://doi.org/10.1038/sj.bjc.6604298CrossRefPubMedPubMedCentral

31.

Mahner S, Eulenburg C, Staehle A, Wegscheider K, Reuss A, Pujade-Lauraine E et al (2013) Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials. Eur J Cancer 49(1):142–149. https://doi.org/10.1016/j.ejca.2012.07.023CrossRefPubMed

32.

Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA (2016) Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol 27:114–21. https://doi.org/10.1093/annonc/mdv500CrossRefPubMed

33.

Lee YY, Lee JW, Lu L, Xu W, Kollara A, Brown T et al (2018) Impact of interval from primary cytoreductive surgery to initiation of adjuvant chemotherapy in advanced epithelial ovarian cancer. Int J Gynaecol Obstet 143(3):325–332. https://doi.org/10.1002/ijgo.12653CrossRefPubMed

34.

Singh S, Guetzko M, Resnick K (2016) Preoperative predictors of delay in initiation of adjuvant chemotherapy in patients undergoing primary debulking surgery for ovarian cancer. Gynecol Oncol 143(2):241–245. https://doi.org/10.1016/j.ygyno.2016.09.004CrossRefPubMed

35.

Horton S, Gauvreau CL (2015) Cancer in Low- and Middle-Income Countries: An Economic Overview. In: Gelband H, Jha P, Sankaranarayanan R, Horton S (eds) Cancer: Disease Control Priorities, vol 3, 3rd edn. The International Bank for Reconstruction and Development / The World Bank; Chapter 16, Washington (DC)

36.

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248–59. https://doi.org/10.1200/JCO.2002.20.5.1248CrossRefPubMed

37.

Hansen JM, Sood AK, Coleman RL, Westin SN, Soliman PT, Ramirez PT, Fellman BM, Schmeler KM, Fleming ND (2018) Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Gynecol Oncol 151(3):428–432. https://doi.org/10.1016/j.ygyno.2018.10.017CrossRefPubMedPubMedCentral

38.

Bisch SP, Jago CA, Kalogera E, Ganshorn H, Meyer LA, Ramirez PT, Dowdy SC, Nelson G (2021) Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology - A systematic review and meta-analysis. Gynecol Oncol 161(1):46–55. https://doi.org/10.1016/j.ygyno.2020.12.035CrossRefPubMed

Titel: Risk Prediction Model for Surgical Complications and Predictors of Delay/Omission of Adjuvant Chemotherapy Post Primary Cytoreduction in Epithelial Ovarian Cancer
verfasst von: Alka Dahiya
Rachel George
Anitha Thomas
Vinotha Thomas
Ajit Sebastian
Abraham Peedicayil
Publikationsdatum: 10.06.2024
Verlag: Springer India
Erschienen in: Indian Journal of Surgery
Print ISSN: 0972-2068
Elektronische ISSN: 0973-9793
DOI: https://doi.org/10.1007/s12262-024-04089-8

Neu im Fachgebiet Chirurgie

US-Team empfiehlt Gastropexie nach Hiatushernien-Op.

14.01.2025
Zwerchfellhernie
Nachrichten

Zur Vermeidung von Rezidiven nach Reparatur einer paraösophagealen Hiatushernie sollte einem US-Team zufolge der Magen bei der Op. routinemäßig an der Bauchwand fixiert werden. Das Ergebnis einer randomisierten Studie scheint dafür zu sprechen.

Mit Lidocain kommt der Darm nicht schneller in Schwung

13.01.2025
Kolektomie
Nachrichten

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

Kein Unterschied bei inadäquaten Schocks zwischen ICD-Typen

24.12.2024
Implantierbarer Kardioverter-Defibrillator
Nachrichten

Inadäquate Schockabgaben sind ein unerwünschter Effekt der Therapie mit implantierbaren Kardioverter-Defibrillatoren. Subkutanen Geräten haftet dabei der Ruf an, dafür besonders anfällig zu sein. Die PRAETORIAN-Forschungsgruppe ist dem nachgegangen.

DCIS: Ist ein Verzicht auf eine Operation möglich?

Mammakarzinom
Nachrichten

Die COMET-Studie zeigt, dass aktives Monitoring bei Patientinnen mit duktalem Carcinoma in situ (DCIS) hinsichtlich der kumulativen Zwei-Jahres-Rate an ipsilateralen invasiven Karzinomen der leitliniengerechten Standardbehandlung nicht unterlegen ist. Dennoch wird von einem Verzicht auf eine Operation abgeraten, wie in einem begleitenden Editorial betont wird.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen